亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Anti-Diabetic and Anti-Obesity Therapeutic

技术优势: Reduces adiposity without elevating plasma triglyceride levelsImproves glucose homeostasis by several potential mechanisms and directly targets both white and brown adipose tissue

技术应用: Anti-diabetic, anti-obesity therapeuticComposition for improving insulin sensitivity of obese and diabetic patients

*Abstract: Obesity and its associated metabolic diseases, including type 2 diabetes, are components of a global epidemic. However, the pharmacological approaches against obesity and metabolic diseases are limited. Research is growing on a secreted protein, Angiopoietin-like 4 (ANGPTL4), that inhibits lipoprotein lipase (LPL) activity and promotes lipolysis in adipocytes.

A UC Berkeley researcher is currently examining the role of ANGPTL4 and variants thereof, particularly the C-terminal fibrinogen-like domain (FLD) of ANGPTL4. Using animal models, the UC researcher found that increasing plasma FLD levels protected the animal from diet-induced obesity without affecting plasma triglyceride levels and improve glucose homeostasis. The discovery targets both white and brown adipose tissue, thus it provides a different approach to reduce obesity, complementing current pharmacological therapies. In addition, the discovery provides compositions and methods to improve insulin sensitivity in type 2 diabetes patients.

欲了解更多信息，请点击这里